YALE PATHOLOGY TISSUE SERVICES SHARED RESOURCE PROJECT SUMMARY/ABSTRACT Yale Pathology Tissue Services (YPTS) was established in 2006 to provide comprehensive tissue-related services and material for investigators at Yale Cancer Center (YCC), Yale University, and beyond. YPTS is committed to providing the maximum amount and quality of human tissue for research at Yale without impacting diagnostic quality, accuracy, and safety in anatomic pathology. YPTS provides a set of policies and standard operating procedures that provide for optimal management of pathology resources, including fresh, frozen, and fixed tissue, and as well as tissue from the Yale Pathology Departmental Archives. During the most recent funding period, 328 Principal Investigators used YPTS. Of the 328, 121 users (37%) were YCC members. The majority of the use was from Developmental Therapeutics (DT) and Genomics, Genetics and Epigenetics (GGE). There are four divisions to YPTS: Tissue Procurement and Distribution (TPD), Developmental Histology and Tissue Microarrays (DHTMA), Clinical Trials Tissue Services (CTTS), and Specialized Translational Services (STS). Together these divisions aim to: 1) provide access to tissue services, 2) maximize the access of translational investigators to human tissues, 3) prepare and submit human tissue for clinical trials around the world, and 4) specialize in quantitative analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-40
Application #
9772265
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
40
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications